Nordic Partnership presents Unclassified EIGA PHARMA ONLINE PRESENTATION Monday FRIDAY 30th May 2008 Europe 11.00 am GMT USA 3PM GMT 2008

Click here to enter presentation for 30th May no software required.

Dial conference number on +44 (0) 207 193 3604 or

If you have skype please click here or

add nordicpartnershipltd to your skype.

Help line please call 44(0) 207 385 1331

Unclassified presentation will last for 30 mins with questions for a further 10 mins, allow a total of 40 mins.

Presentation Agenda

1. Introduction to the team and professional advisors

2. Scientific presentation

3. Corporate structure

4. Source and application of funds summary

5. Summary of the opportunity

6. Questions

Your will need the following:-

1. Computer online with high speed access broad band

2. Sound and working microphone

2. A working internet browser

3. Software downloaded from skype web site (takes 1 mins to install) and add nordicpartnershipltd to your skype contacts

EIGA PHARMA would like to thank its sponsors Nordic Partnership Ltd and Instant presenter for assisting with this presentation.

Eiga Pharma gives Nordic Partnership Ltd Exclusive Mandate to raise £5 million

Nordic Partnerhsip Ltd has been given an exclusive mandate to assist Eiga with the development of the Eiga Project which includes The Nano Particle Magnetic Separator & application of protein complex for cancer treatment and diagnostics  and to raise funds for the Eiga Project by building the professional team of advisors.

Disclaimer

The information contained on this web site is not an invitation or solicitation to invest in the shares of the company. It is produced for the purpose of description of  the activities of the company, the research, the products and treatments. Any use of this information  for the purpose of a financial transaction should be conducted through an independent  financial advisor or professional consultant.

Jonathan de Rin, Ruben Berg, Anjam Butt and Gavin Pell are working on:-

1. Due diligence materials
   
2. Advisory Board
   
3. Key material agreements
   
4. Clinical trial outsourcing
   
5. Private Placement memorandum
   
6. Corporate structure
   
7. IP transfer agreement
   
8. Share holder agreement
   
9. Pathfinder strategy to eventually list the company on the London AIM market
   

EIGA PHARMA PROJECT BACKGROUND

The teams work is based on the original ideas developed by Judah Folkman in the field of angiogenesis. The team has developed proprietry research in the field of cancer treatment, diagnostics and a specific Magnet Nano Particle Separation device. 

Judah Folkman our Hero has sadly died 

Eiga Team would like to thank Judah for all his kind help and support on our project and he will be sadly missed

Judah Folkman MD 1933-2008

Please click here and take the time to watch a small selection of these videos that will help you to understand the work of Judah Folkman

Click here to see a "Thank you for saving my life"

Click here for a Memoriam to a Giant of Cancer therapy 

EIGA PHARMA RESEARCH, PRODUCTS AND INVENTIONS

The Eiga team's work is centered around three principal areas.

1. Magnetic Nano Particle Separator 
2. Cancer diagnostics 
3.  Autoimmune response of cancer 

1. Magnetic Nano Particle Separator 

Magnetic Separator device is protected by patent 

The invention relates to the field of ecology, biotechnology, molecular biology, biological chemistry, immunology, in particular to detection of components with the help of specific interactions between the latter and a microcarrier comprising a receptor immobilized thereon for defining said components. Increasing the reliability of simultaneous detection of a number of components in a mixture, making the analysis cheaper and less time-consuming, extending the range of markers used as well as providing the possibility of visual registration of the contents of a number of components in a mixture is achieved by a method and a device for simultaneous detection of a number of components in a mixture, said method comprising a step of reacting of the components under analysis with the specific receptors immobilized on the surfaces of microcarriers of various forms. As a result of formation of specific complexes a mobility of microcarriers under the influence of a physical field is changed. Due to the change of mobility of microcarriers under the influence of a physical field a separation into a fraction of non-reacted microcarriers with unchanged mobility, and a fraction or fractions of microcarriers with changed mobility. Since each type of a specific receptor is bound to its marked microcarrier the analysis of just a marker characteristic of microcarriers with changed mobility under the influence of a physical field will reveal the availability of the component which has reacted with this microcarrier in the mixture under analysis. Under a physical field as in the case described a gravitation field, an electric field or a magnetic field as well as combinations of .the above is understood. A more efficient reacting of the mixture components with a minimum amount of microcarriers , provision of an efficient and operation-saving separation of microcarriers is achieved in a convenient for sterilization separating chamber where the process of retaining the microcarriers on the walls of a separating chamber and removing them into the collector is actually continuous.

2005 discovery made 

Method and device for simultaneous detection of multiple components in a mixture.

Document Type and Number

Europea Patent EP1365241

Code A2

Treatment method and diagnostics for early cancer are protected by patent application.

Protein complexes for prevention and treatment of diseases with angiogenesis disorders.

Doucment Type and Number

Wipo Patent WO/2008/006187

Code A2

2.Cancer diagnostics 
3. Autoimmune response of cancer

The invention relates to the medical field, and in particular, to protein complexes and application thereof for the correction of autoimmune processes in human or animal bodies and also to a research of biochemical mechanisms of diseases with angiogenesis disorders. The protein complexes claimed comprise an antigen and an effector portion attached thereto wherein said antigen presents an angiogenic factor. An angiogenic factors of a protein complexes could be both pro-angiogenic and anti-angiogenic. An effector portion can either show of immunomodulating activity, or provide the specific influence on a target immunocompetent cells Moreover, it can be made in the form of a polymer carrier for depleting of target autoantibodies and immunocompetent cells. There are also claimed the use of new protein complexes, the new methods of treatment of diseases with angiogenesis disorders and a new method and a new test-system for monitoring of angiogenesis disorders for use in the above methods of treatment. The inventors are emphasizing the role of autoimmune mechanism in origin of malignant growth and the importance of subject of the invention for early cancer diagnostics, prevention and treatment

Started clinical trials Feb 2007